Article

Addition of docetaxel ups survival in esophageal and gastric cancers

Elizabeth whittington blog image

Patients whose advanced esophageal or gastric cancers return after treatment often don't have many treatment options. Currently, physicians treat patients with second-line chemotherapy, but until now, there haven't been any large studies to really back up the strategy. Fortunately, the COUGAR-02 study shows that we're on the right track. In the phase 3 study, patients with advanced cancer whose disease had progressed within six months of chemotherapy received either docetaxel or active symptom control. The addition of docetaxel (Taxotere) improved median overall survival from 3.6 months to 5.2 months, and nearly half of patients' cancers were stabilized after chemotherapy. About 20 percent of patients did experience a severe toxicity, though. In light of the results, researchers hope doctaxel will be considered a new standard of treatment for patients with advanced esophageal or gastric cancer. The results were first announced this past January at the ASCO Gastrointestinal Cancers Symposium.

Related Videos
Image of Dr. Goy.
Image of bald man.
Dr. Tycel Phillips is an Associate Professor in the Division of Lymphoma, Department of Hematology and Hematopoietic Cell Transplantation, at City of Hope in Duarte, California.
Image of Dr. Salani.
Dr. Debu Tripathy is a professor and chairman of the Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, in Houston, and the editor-in-chief of CURE®.
Dr. Suneel Kamath is an assistant professor of medicine at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, in Ohio.
Image of Dr. Fakih.
Dr. Catherine Wu is chief of the Division of Stem Cell Transplantation and Cellular Therapies at Dana-Farber Cancer Institute, and institute member at the Broad Institute of MIT and Harvard, in Boston, Massachusetts.
Dr. John Oertle discusses the key benefits to come from patients with cancer connecting with support networks, advocacy groups and resources.
Dr. Gabriel A. Brooks discussed the recent FDA product labeling update for Xeloda and 5-FU.
Related Content